Compassionate Use of Stannsoporfin in Addition to Phototherapy to Reduce the Need for Exchange Transfusions in Term and Near-Term Infants

This study is enrolling participants by invitation only.
Information provided by:
InfaCare Pharmaceuticals Corporation Identifier:
First received: August 16, 2010
Last updated: August 17, 2010
Last verified: August 2010
The purpose of this protocol is to make Stanate® (Stannsoporfin, tin-mesoporphyin) available to infants who meet the following criteria: 1) the infant has a very high level of bilirubin without an adequate clinical response to phototherapy 2)requires exchange transfusion and 3) the family refuses to allow the administration of blood products, particularly on religious grounds, such as the Jehovah's Witness Community.

Condition Intervention
Neonatal Hyperbilirubinemia
Neonatal Jaundice
Drug: Stanate®

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions in Term and Near-Term Infants

Resource links provided by NLM:

Further study details as provided by InfaCare Pharmaceuticals Corporation:

Primary Outcome Measures:
  • safety [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    Total serum builirubin, CBC, LFTs and other safety assessments are done over the seven day period following drug administration. Adverse events are collected for 30 days.

Estimated Enrollment: 50
Study Start Date: October 2003
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stanate® Drug: Stanate®
Single IM injection of 4.5 mg/kg


Ages Eligible for Study:   up to 1 Week
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
  1. Term or near term neonate
  2. Elevated serum bilirubin
  3. Failing Phototherapy
  4. Requires Exchange Transfusion
  5. Family refuses exchange transfusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01183988

Sponsors and Collaborators
InfaCare Pharmaceuticals Corporation
Study Director: Warren W Wasiewski, MD InfaCare Pharmaceutical Corporation
  More Information

Responsible Party: Warren W. Wasiewski, MD, Chief Medical Officer, InfaCare Pharmaceutical Corporation Identifier: NCT01183988     History of Changes
Other Study ID Numbers: 64,185-99A-3W
Study First Received: August 16, 2010
Last Updated: August 17, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by InfaCare Pharmaceuticals Corporation:
exchange transfusion

Additional relevant MeSH terms:
Hyperbilirubinemia, Neonatal
Jaundice, Neonatal
Infant, Newborn, Diseases
Pathologic Processes
Signs and Symptoms
Skin Manifestations
Tin mesoporphyrin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on November 27, 2015